FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034233121> ?p ?o ?g. }

• W2034233121 endingPage "817" @default.
• W2034233121 startingPage "813" @default.
• W2034233121 abstract "Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study.BackgroundTacrolimus is a relatively new calcineurin inhibitor that has been increasingly used in transplant medicine. The objective of the current work is to report our preliminary experience with tacrolimus in the treatment of diffuse proliferative glomerulonephritis in systemic lupus erythematosus (SLE).MethodsNine consecutive patients who fulfilled the American College of Rheumatology criteria for SLE and with biopsy-proven diffuse proliferative glomerulonephritis were recruited for an open-labeled trial with prednisolone and oral tacrolimus (0.1 mg/kg/day for 2 months, followed by 0.06 mg/kg/day). Prospective data on renal response and serologic lupus activity were collected. The efficacy and safety of this regimen was reported.ResultsBaseline characteristics of the patients were: mean age 33.3 ± 12 years, women to men ratio 2:1, serum creatinine 94.2 ± 46 umol/L, daily proteinuria 4.56 ± 2.4 g, seven (78%) patients were nephrotic, three (33%) were hypertensive, and four (44%) had elevated serum creatinine at the time of renal biopsy. At 6 months of therapy, complete and partial renal response was achieved in six (67%) and two (22%) patients, respectively. Significant improvement in proteinuria, hemoglobin, serum albumin, and C3 levels was observed in comparison with baseline values, starting at the second month. Tacrolimus was generally well tolerated, except for two patients who developed transient hyperglycemia. Infective complications, amenorrhea, hypertrichosis, gingivitis, new-onset hypertension, and significant increase in serum creatinine were not reported.ConclusionTacrolimus is an effective option for induction treatment of SLE-diffuse proliferative glomerulonephritis. Further trials are necessary to determine the optimal dosage and duration of therapy, and its efficacy in comparison to standard regimens. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Tacrolimus is a relatively new calcineurin inhibitor that has been increasingly used in transplant medicine. The objective of the current work is to report our preliminary experience with tacrolimus in the treatment of diffuse proliferative glomerulonephritis in systemic lupus erythematosus (SLE). Nine consecutive patients who fulfilled the American College of Rheumatology criteria for SLE and with biopsy-proven diffuse proliferative glomerulonephritis were recruited for an open-labeled trial with prednisolone and oral tacrolimus (0.1 mg/kg/day for 2 months, followed by 0.06 mg/kg/day). Prospective data on renal response and serologic lupus activity were collected. The efficacy and safety of this regimen was reported. Baseline characteristics of the patients were: mean age 33.3 ± 12 years, women to men ratio 2:1, serum creatinine 94.2 ± 46 umol/L, daily proteinuria 4.56 ± 2.4 g, seven (78%) patients were nephrotic, three (33%) were hypertensive, and four (44%) had elevated serum creatinine at the time of renal biopsy. At 6 months of therapy, complete and partial renal response was achieved in six (67%) and two (22%) patients, respectively. Significant improvement in proteinuria, hemoglobin, serum albumin, and C3 levels was observed in comparison with baseline values, starting at the second month. Tacrolimus was generally well tolerated, except for two patients who developed transient hyperglycemia. Infective complications, amenorrhea, hypertrichosis, gingivitis, new-onset hypertension, and significant increase in serum creatinine were not reported. Tacrolimus is an effective option for induction treatment of SLE-diffuse proliferative glomerulonephritis. Further trials are necessary to determine the optimal dosage and duration of therapy, and its efficacy in comparison to standard regimens." @default.
• W2034233121 created "2016-06-24" @default.
• W2034233121 creator A5006185236 @default.
• W2034233121 creator A5031101141 @default.
• W2034233121 creator A5033947419 @default.
• W2034233121 creator A5052148741 @default.
• W2034233121 creator A5072181664 @default.
• W2034233121 date "2005-08-01" @default.
• W2034233121 modified "2023-09-30" @default.
• W2034233121 title "Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study" @default.
• W2034233121 cites W143318074 @default.
• W2034233121 cites W1971234219 @default.
• W2034233121 cites W1993619587 @default.
• W2034233121 cites W2007829650 @default.
• W2034233121 cites W2009390925 @default.
• W2034233121 cites W2014325694 @default.
• W2034233121 cites W2021736794 @default.
• W2034233121 cites W2036892337 @default.
• W2034233121 cites W2037857651 @default.
• W2034233121 cites W2046412737 @default.
• W2034233121 cites W2059676586 @default.
• W2034233121 cites W2082892740 @default.
• W2034233121 cites W2088942316 @default.
• W2034233121 cites W2094633801 @default.
• W2034233121 cites W2107871522 @default.
• W2034233121 cites W2114495250 @default.
• W2034233121 cites W2126372666 @default.
• W2034233121 cites W2145552180 @default.
• W2034233121 cites W2146203649 @default.
• W2034233121 cites W2165814426 @default.
• W2034233121 cites W2166764883 @default.
• W2034233121 cites W2325870812 @default.
• W2034233121 doi "https://doi.org/10.1111/j.1523-1755.2005.00461.x" @default.
• W2034233121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16014060" @default.
• W2034233121 hasPublicationYear "2005" @default.
• W2034233121 type Work @default.
• W2034233121 sameAs 2034233121 @default.
• W2034233121 citedByCount "124" @default.
• W2034233121 countsByYear W20342331212012 @default.
• W2034233121 countsByYear W20342331212013 @default.
• W2034233121 countsByYear W20342331212014 @default.
• W2034233121 countsByYear W20342331212015 @default.
• W2034233121 countsByYear W20342331212016 @default.
• W2034233121 countsByYear W20342331212017 @default.
• W2034233121 countsByYear W20342331212018 @default.
• W2034233121 countsByYear W20342331212019 @default.
• W2034233121 countsByYear W20342331212020 @default.
• W2034233121 countsByYear W20342331212021 @default.
• W2034233121 countsByYear W20342331212022 @default.
• W2034233121 countsByYear W20342331212023 @default.
• W2034233121 crossrefType "journal-article" @default.
• W2034233121 hasAuthorship W2034233121A5006185236 @default.
• W2034233121 hasAuthorship W2034233121A5031101141 @default.
• W2034233121 hasAuthorship W2034233121A5033947419 @default.
• W2034233121 hasAuthorship W2034233121A5052148741 @default.
• W2034233121 hasAuthorship W2034233121A5072181664 @default.
• W2034233121 hasBestOaLocation W20342331211 @default.
• W2034233121 hasConcept C126322002 @default.
• W2034233121 hasConcept C126894567 @default.
• W2034233121 hasConcept C141071460 @default.
• W2034233121 hasConcept C2775934546 @default.
• W2034233121 hasConcept C2776715498 @default.
• W2034233121 hasConcept C2776912625 @default.
• W2034233121 hasConcept C2779134260 @default.
• W2034233121 hasConcept C2779561371 @default.
• W2034233121 hasConcept C2779912601 @default.
• W2034233121 hasConcept C2780091579 @default.
• W2034233121 hasConcept C2780306776 @default.
• W2034233121 hasConcept C2781087799 @default.
• W2034233121 hasConcept C2909675724 @default.
• W2034233121 hasConcept C2911091166 @default.
• W2034233121 hasConcept C71924100 @default.
• W2034233121 hasConcept C90924648 @default.
• W2034233121 hasConceptScore W2034233121C126322002 @default.
• W2034233121 hasConceptScore W2034233121C126894567 @default.
• W2034233121 hasConceptScore W2034233121C141071460 @default.
• W2034233121 hasConceptScore W2034233121C2775934546 @default.
• W2034233121 hasConceptScore W2034233121C2776715498 @default.
• W2034233121 hasConceptScore W2034233121C2776912625 @default.
• W2034233121 hasConceptScore W2034233121C2779134260 @default.
• W2034233121 hasConceptScore W2034233121C2779561371 @default.
• W2034233121 hasConceptScore W2034233121C2779912601 @default.
• W2034233121 hasConceptScore W2034233121C2780091579 @default.
• W2034233121 hasConceptScore W2034233121C2780306776 @default.
• W2034233121 hasConceptScore W2034233121C2781087799 @default.
• W2034233121 hasConceptScore W2034233121C2909675724 @default.
• W2034233121 hasConceptScore W2034233121C2911091166 @default.
• W2034233121 hasConceptScore W2034233121C71924100 @default.
• W2034233121 hasConceptScore W2034233121C90924648 @default.
• W2034233121 hasIssue "2" @default.
• W2034233121 hasLocation W20342331211 @default.
• W2034233121 hasLocation W20342331212 @default.
• W2034233121 hasOpenAccess W2034233121 @default.
• W2034233121 hasPrimaryLocation W20342331211 @default.
• W2034233121 hasRelatedWork W1589032605 @default.
• W2034233121 hasRelatedWork W1844022072 @default.
• W2034233121 hasRelatedWork W1903400040 @default.
• W2034233121 hasRelatedWork W2012997553 @default.

• next